Hematology 1
Normochromic, normocytic anemia; elevated ferritin; low iron and TIBC
Anemia of inflammation
Testing indicated for moderate- to high-probability Wells score for DVT and PE
Duplex imaging for DVT; CT angiography for PE
Monoclonal protein <3 g/dL, clonal plasma cells <10% of marrow cellularity, no end-organ damage
MGUS
Lab finding of citrate toxicity during massive transfusion
Hypocalcemia
Post-DVT pain, edema, stasis dermatitis
Postthrombotic syndrome
Chronic hemolytic anemia, spherocytes, negative DAT
Hereditary spherocytosis
DOAC for patients receiving dialysis
Apixaban
Most common indications for autologous HSCT
Multiple myeloma, relapsed aggressive lymphoma
Management of hemophilia A, minor bleeding
Desmopressin
Treatment of asymptomatic ET in older patients
Hydroxyurea and low-dose aspirin
Hemolytic anemia, bite cells, Heinz bodies
G6PD deficiency
Deficiency causing heparin resistance and VTE
Antithrombin deficiency
MGUS with unexplained kidney disease
Monoclonal gammopathy of renal significance
Safe ITP platelet count during pregnancy
>30,000/µL (30 × 109/L)
Duration of VTE prophylaxis in pregnant person with SCD
While hospitalized and 6 weeks postpartum
Erythrocytosis, positive JAK2
Polycythemia vera
HIT therapy duration with documented thromboembolic event
At least 3 months
MDS gold standard diagnostic test
Bone marrow biopsy
Transfusion for warm autoimmune hemolytic anemia without crossmatch compatible blood
ABO- and Rh-matched transfusion
Genetic testing for abdominal thrombosis, splenomegaly, portal hypertension
JAK2
Hereditary hemochromatosis treatment
Phlebotomy
Outpatient therapy for acute low-risk PE
Apixaban, rivaroxaban
IgM paraprotein, hyperviscosity
Waldenström macroglobulinemia
Noncardiogenic pulmonary edema 6 hours after transfusion
TRALI
Preoperative management of patient with SCD for surgery requiring general anesthesia
Simple transfusion with target hemoglobin 10 g/dL